カテゴリ： GlobalData, アメリカ, 企業調査

Regeneron Pharmaceuticals Inc (REGN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Regeneron Pharmaceuticals Inc (REGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10118
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：132
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company, which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company’s six US FDA-approved medicines and product candidates in development help patients with eye diseases, asthma, pain, cancer and heart, allergic, inflammatory and infectious diseases. It develops products based on its VelociSuite technology platforms, which include VelociGene, VelocImmune, VelociMouse, VelociMab and other related technologies. Regeneron also has various product candidates under clinical development for treating asthma, pain, cancer, atopic dermatitis and infectious diseases. It has subsidiaries in Belgium, Spain, Ireland, the Netherlands, the US and the UK. Regeneron is headquartered in Tarrytown, New York, the US.

Regeneron Pharmaceuticals Inc (REGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 16
Venture Financing 17
Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 17
Private Equity 19
TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For US$161 Million 19
Partnerships 20
Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 20
Replimune Enters into Co-Development Agreement with Regeneron Pharma 22
Regeneron Pharma Enters into Agreement with Alnylam Pharma 23
Regeneron Pharma and ISA Pharma Enter into Partnership 24
Regeneron Pharma Enters into Co-Development Agreement with Decibel Therapeutics 25
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 26
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 27
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 28
Inovio Pharma and Regeneron Pharma Enter into Agreement 29
Indivumed Enters into Agreement with Regeneron Pharma 30
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 31
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 33
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 34
Bayer Enters into Co-Development Agreement with Regeneron Pharma 35
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 36
Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 37
Regeneron Pharma Enters into Development Agreement with BARDA 38
Regeneron Pharma Amends Co-Development Agreement with Sanofi 39
Regeneron Pharma Amends Co-Development Agreement with Sanofi 41
Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 42
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 43
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 44
Licensing Agreements 46
Kiniksa Pharma Enters into Licensing Agreement with Regeneron 46
Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 47
Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 48
Regeneron Pharma Enters into Licensing Agreement with MedImmune 50
Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 51
Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 52
Regeneron Pharmaceuticals Inc – Key Competitors 53
Regeneron Pharmaceuticals Inc – Key Employees 54
Regeneron Pharmaceuticals Inc – Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Recent Developments 57
Financial Announcements 57
Nov 06, 2018: Regeneron reports third quarter 2018 financial and operating results 57
Aug 02, 2018: Regeneron reports second quarter 2018 financial and operating results 59
May 03, 2018: Regeneron Reports First Quarter 2018 Financial And Operating Results 62
Feb 08, 2018: Regeneron Reports Fourth Quarter and Full Year 2017 Financial Results 65
Nov 08, 2017: Regeneron Reports Third Quarter 2017 Financial and Operating Results 68
Aug 03, 2017: Regeneron Reports Second Quarter 2017 Financial and Operating Results 71
May 04, 2017: Regeneron Reports First Quarter 2017 Financial And Operating Results 74
Feb 09, 2017: Regeneron Reports Fourth Quarter And Full Year 2016 Financial And Operating Results 77
Corporate Communications 81
Jun 23, 2018: Regeneron Announces Departure of Michael Aberman, M.D., Senior Vice President of Strategy and Investor Relations 81
Feb 12, 2018: Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial 82
Jan 31, 2017: Tony Coles, M.D., Elected To Regeneron Board Of Directors 83
Legal and Regulatory 84
Mar 19, 2018: Regeneron Pharmaceuticals Announce Regarding Novartis Complaint on ‘688 Patent 84
Dec 27, 2017: Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron’s Petition to Rehear the Panel’s Decision Affirming Merus’ Inequitable Conduct Claim Against Regeneron 85
Jul 28, 2017: U.S. Court of Appeals for the Federal Circuit Affirms Merus’ Inequitable Conduct Claim Against Regeneron 86
Government and Public Interest 87
Aug 07, 2018: Regeneron: Statement regarding new CMS guidance for part B drugs 87
Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease 88
Mar 13, 2018: Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease 90
Mar 22, 2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World’s Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis 92
Product News 94
10/03/2018: Onco360 selected as the exclusive specialty pharmacy for libtayo (cemiplimab-rwlc) limited distribution pharmacy network 94
09/28/2018: FDA approves Libtayo (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma 95
09/08/2017: Sanofi and Regeneron Announce That Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma 97
08/23/2018: Intellia Therapeutics presents progress in lead in vivo program at cold spring harbor laboratory’s fourth meeting on genome engineering: the CRISPR-Cas revolution 98
08/17/2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis 99
05/31/2018: Regeneron’s Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak 100
04/25/2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection 101
02/08/2017: Appeals Court Grants Stay of Permanent Injunction for Praluent (alirocumab) During Appeals Process 102
01/13/2017: Sanofi and Regeneron File Notice of Appeal and Motion to Stay (Suspend) Injunction with Federal Circuit Court of Appeals in Patent Case Regarding Praluent (alirocumab) Injection 103
Product Approvals 104
Apr 30, 2018: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma 104
Apr 03, 2018: EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma 105
Clinical Trials 106
Oct 08, 2018: Libtayo (Cemiplimab-RWLC) data at ESMO 2018 congress provide new insights in six tumor types under investigation 106
Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints 108
Jun 04, 2018: New England Journal of Medicine Publishes pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma 109
May 16, 2018: Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO 111
Feb 27, 2018: Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology 112
Dec 13, 2017: Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma 113
Nov 27, 2017: Regeneron Provides Update on Eylea (Aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program 114
Nov 07, 2017: Regeneron and Sanofi to Present New Analyses from the Praluent (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017 115
Nov 01, 2017: Regeneron to Share Clinical Progress of Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting 117
Nov 01, 2017: Regeneron to Share Clinical Progress of REGN1979 in B-Cell Lymphomas at the 2017 ASH Annual Meeting 118
Aug 25, 2017: Regeneron and Sanofi to Present New Analyses from Praluent Injection Trials at the ESC Congress 2017 119
Jun 11, 2017: Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes 121
Jun 11, 2017: Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia 123
Jun 04, 2017: Regeneron And Sanofi Present Positive Study Results For Investigational PD-1 Antibody REGN2810 At American Society Of Clinical Oncology (Asco) Annual Meeting 125
Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions 126
Other Significant Developments 128
Sep 11, 2018: Governor Cuomo announces Regeneron to create 1,500 biotech jobs in major New York expansion 128
Aug 09, 2018: Ebola virus experts discover powerful, new approach for future therapeutics 130
May 18, 2018: Experimental MERS Treatments Enter Clinical Trial 131
Appendix 132
Methodology 132
About GlobalData 132
Contact Us 132
Disclaimer 132

List of Tables
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Regeneron Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 16
Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 17
TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For US$161 Million 19
Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 20
Replimune Enters into Co-Development Agreement with Regeneron Pharma 22
Regeneron Pharma Enters into Agreement with Alnylam Pharma 23
Regeneron Pharma and ISA Pharma Enter into Partnership 24
Regeneron Pharma Enters into Co-Development Agreement with Decibel Therapeutics 25
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 26
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 27
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 28
Inovio Pharma and Regeneron Pharma Enter into Agreement 29
Indivumed Enters into Agreement with Regeneron Pharma 30
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 31
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 33
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 34
Bayer Enters into Co-Development Agreement with Regeneron Pharma 35
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 36
Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 37
Regeneron Pharma Enters into Development Agreement with BARDA 38
Regeneron Pharma Amends Co-Development Agreement with Sanofi 39
Regeneron Pharma Amends Co-Development Agreement with Sanofi 41
Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 42
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 43
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 44
Kiniksa Pharma Enters into Licensing Agreement with Regeneron 46
Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 47
Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 48
Regeneron Pharma Enters into Licensing Agreement with MedImmune 50
Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 51
Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 52
Regeneron Pharmaceuticals Inc, Key Competitors 53
Regeneron Pharmaceuticals Inc, Key Employees 54
Regeneron Pharmaceuticals Inc, Other Locations 56
Regeneron Pharmaceuticals Inc, Subsidiaries 56

List of Figures
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Regeneron Pharmaceuticals Inc (REGN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Samsung Biologics Co Ltd (207940)：製薬・医療：M&Aディール及び事業提携情報
    Summary Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company. The company’s business activities include process development, contract manufacturing, aseptic fill and finish and project management. Samsung Biologics cell culture development process include …
  • Hyundai Heavy Industries Co., Ltd.：企業の戦略・SWOT・財務情報
    Hyundai Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hyundai Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Ultrapar Participacoes SA (UGPA3)：企業の財務・戦略的SWOT分析
    Ultrapar Participacoes SA (UGPA3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Gavilon Agriculture Holdings Co：石油・ガス：M&Aディール及び事業提携情報
    Summary Gavilon Agriculture Holdings Co (Gavilon) is a merchandising service provider that offers essential agricultural commodities and services. The company’s products include grains and oilseeds, feed ingredients, fertilizers, and food ingredients, among others. Its feed ingredients comprise anim …
  • ALK-Abello AS (ALK B)：製薬・医療：M&Aディール及び事業提携情報
    Summary ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It markets diagnostics and other services to allergy clinics. The company's allergy immunotherapy product portfolio includes tablet-based …
  • Kelly Services, Inc.：企業の戦略・SWOT・財務分析
    Kelly Services, Inc. - Strategy, SWOT and Corporate Finance Report Summary Kelly Services, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Copperbelt Energy Corporation PLC (CEC)-エネルギー分野：企業M&A・提携分析
    Summary Copperbelt Energy Corporation PLC (CEC) is an electric utility that generates, transmits, distributes and sells energy. The company generates electricity from hydro, solar, gas and thermal sources; transmits electricity through a network of transmission lines and high voltage substations and …
  • Vifor Pharma AG-製薬・医療分野：企業M&A・提携分析
    Summary Vifor Pharma AG (Vifor Pharma), a subsidiary of Galenica Ltd is a healthcare service provider that discovers, develops, manufactures, and commercializes prescription and over the counter pharmaceutical products for the treatment of iron replacement therapy. The company offers products for tr …
  • Uni-President China Holdings Ltd：企業の戦略・SWOT・財務分析
    Uni-President China Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Uni-President China Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Einstein Noah Restaurant Group, Inc. (Foodservice)：企業の戦略・SWOT・財務情報
    Einstein Noah Restaurant Group, Inc. (Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Einstein Noah Restaurant Group, Inc. (Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's struct …
  • Commonwealth Edison Company：電力：M&Aディール及び事業提携情報
    Summary Commonwealth Edison Company (ComEd) a subsidiary of Exelon Corporation is an electric utility that is engaged in the distribution of electricity to home and business customers. The utility’s business activities include lighting, retro-commissioning, HVAC, new construction, custom projects, i …
  • Medikit Co Ltd (7749)：企業の財務・戦略的SWOT分析
    Summary Medikit Co Ltd (Medikit) is a medical equipment provider that offers vascular devices. The company offers IV catheter, hemodialysis and intervention products. Its products include supercath Z3V, supercath 5 safety IV catheter, supercath AZ, supercath CLS, i-works, seiha, parent plus, parent …
  • Bando Chemical Industries, Ltd. (5195)：企業の財務・戦略的SWOT分析
    Bando Chemical Industries, Ltd. (5195) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • The GPT Group：企業のM&A・事業提携・投資動向
    The GPT Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The GPT Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Southern Co：企業の発電所・SWOT分析2018
    Southern Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (execut …
  • Biosense Webster Inc-医療機器分野：企業M&A・提携分析
    Summary Biosense Webster Inc (Biosense Webster), a subsidiary of Johnson & Johnson is a medical device company that offers cardiac arrhythmias products. The company designs, manufactures and markets products for diagnosis and treatment of cardiac arrhythmias. Its products comprise ablation catheters …
  • Panda Green Energy Group Ltd：企業のM&A・事業提携・投資動向
    Panda Green Energy Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Panda Green Energy Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Wood Group Mustang Inc-石油・ガス分野：企業M&A・提携分析
    Summary Wood Group Mustang, Inc. (Wood Group Mustang), a subsidiary of John Wood Group PLC is an engineering management company. It provides engineering, procurement, and construction management (EPC) services to clients across diverse end markets. The company’s service portfolio comprises design an …
  • Harbin Bank Co Ltd：企業の戦略・SWOT・財務分析
    Harbin Bank Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Harbin Bank Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • IDInvest Partners：企業のM&A・事業提携・投資動向
    IDInvest Partners - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IDInvest Partners Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆